BMS, Gilead to make cancer drug combo; SAFC plant certified for high potency APIs;

> Bristol-Myers Squibb ($BMY) and Gilead Sciences ($GILD) have joined forces to develop and manufacture a fixed-dose combination of BMS's protease inhibitor Reyataz and Gilead's booster drug, Cobicistat. Release

> Sigma-Aldrich ($SIAL) unit SAFC has earned SafeBridge Certification for its commercial-scale high-potency API facility in Verona, WI. Announcement

> Logistics challenges in the Indian market include lack of infrastructure and skilled labor, maintaining the quality of goods during transit and a "crippling" lack of multimodal transport solutions. Story

> Process automation specialist Endress+Hauser has acquired a stake in Finesse Solutions, maker of sensors, hardware and software for bioprocess engineering. Release

> The U.K. Department of Health has renewed its long-term contract with Movianto for storage and distribution of childhood vaccines. Announcement

> PharmaSecure has won a $3.9 million investment from several venture firms to create new applications for India's drug serialization requirements that go into effect next year. News

> Israeli police have seized more than 30 packages of counterfeit diet pills, which contain the active ingredients in the anti-depressant Prozac, Valium and an amphetamine. Item

> CMC Biologics will provide manufacturing and process development services to Daiichi Sankyo for clinical-stage antibodies. Release